全部分类
  • 2',3',5'-triacetyl-5-Azacytidine
2',3',5'-triacetyl-5-Azacytidine的可视化放大

2',3',5'-triacetyl-5-Azacytidine

A prodrug form of 5-azacytidine

此产品仅用于科学研究,我们不为任何个人用途提供产品和服务

2',3',5'-triacetyl-5-Azacytidine的二维码
  • 库存: 现货
可选规格
  • 包装
    价格
    促销价
    数量
  • 5mg
    ¥1037.00
    830.00
    - +
  • 10mg
    ¥1937.00
    1550.00
    - +
  • 50mg
    ¥8062.00
    6450.00
    - +
  • 100mg
    ¥13975.00
    11180.00
    - +
已选 0 0
金额: ¥0.00
首页 收藏
  • 货号: ajci9792
  • CAS: 10302-78-0
  • 别名: 三乙酰基-阿扎胞苷
  • 分子式: C14H18N4O8
  • 分子量: 370.3
  • 纯度: >98%
  • 溶解度: ≤30mg/ml in ethanol;30mg/ml in DMSO;30mg/ml in dimethyl formamide
  • 储存: Store at -20°C
  • 库存: 现货

Background

2',3',5'-triacetyl-5-Azacytidine (TAC) is the lead prodrug form of 5-azacytidine which may be rapidly absorbed after oral administration [1]. 5-Azacytidine is an inhibitor of DNA methyltransferase [2].


The DNA methyltransferase belongs to a family of enzymes involved in catalyzing the transfer of a methyl group to DNA. DNA methylation has been implicated in regulating gene expression in normal and malignant cells [2].


In vivo: In CD-1 mice, oral administration of TAC for five days per week for 2 weeks didn’t result in animal deaths and weight loss, but induced changes in hematological parameters, lymph nodes, bone marrow, and duodenal epithelium. TAC inhibited global DNA methylation in the spleen and gut. In an in vivo L1210 leukemia model, TAC exhibited antineoplastic activity [1].

参考文献:
[1] Ziemba A, Ramirez M C, Freeman B, et al.? Abstract# 3369: Development of oral demethylating agents for the treatment of myelodysplastic syndrome[J]. 2009.
[2] Brueckner B, Boy R G, Siedlecki P, et al.? Epigenetic reactivation of tumor suppressor genes by a novel small-molecule inhibitor of human DNA methyltransferases[J]. Cancer research, 2005, 65(14): 6305-6311.

没有评价数据

温馨提示 ×
商品已成功加入购物车!
购物车共 0 件商品
去购物车结算